drugset / Trial / NCT01089127

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127

Phase 3 Completed 552 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.

Timeline

Start
2010-03
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 18.75 ug Inhaled
Subject Indacaterol Other / unclassified 37.5 ug Inhaled
Subject Indacaterol Other / unclassified 75 ug Inhaled
Subject Indacaterol Other / unclassified 150 ug Inhaled
Comparator Salmeterol Other / unclassified 50 ug Inhaled